Dulce Papy-Garcia

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9910738/publications.pdf

Version: 2024-02-01

30 papers	2,070 citations	361413 20 h-index	477307 29 g-index
33 all docs	33 docs citations	33 times ranked	3234 citing authors

#	Article	IF	Citations
1	Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E3138-47.	7.1	683
2	Improved and simple micro assay for sulfated glycosaminoglycans quantification in biological extracts and its use in skin and muscle tissue studies. Glycobiology, 2003, 13, 647-653.	2.5	293
3	Heparan Sulfate Is a Cellular Receptor for Purified Infectious Prions. Journal of Biological Chemistry, 2005, 280, 17062-17067.	3.4	150
4	HS3ST2 expression is critical for the abnormal phosphorylation of tau in Alzheimerâ€™s disease-related tau pathology. Brain, 2015, 138, 1339-1354.	7.6	75
5	Nondegradative Sulfation of Polysaccharides. Synthesis and Structure Characterization of Biologically Active Heparan Sulfate Mimetics. Macromolecules, 2005, 38, 4647-4654.	4.8	74
6	A novel generation of heparan sulfate mimetics for the treatment of prion diseases. Journal of General Virology, 2003, 84, 2595-2603.	2.9	73
7	The role of heparan sulfates in protein aggregation and their potential impact on neurodegeneration. FEBS Letters, 2018, 592, 3806-3818.	2.8	63
8	Human Plasmin Enzymatic Activity Is Inhibited by Chemically Modified Dextrans. Journal of Biological Chemistry, 2000, 275, 29383-29390.	3.4	58
9	Pharmacological studies of RGTA11, a heparan sulfate mimetic polymer, efficient on muscle regeneration. Journal of Biomedical Materials Research Part B, 2002, 62, 525-531.	3.1	57
10	Elastin-like recombinamers-based hydrogel modulates post-ischemic remodeling in a non-transmural myocardial infarction in sheep. Science Translational Medicine, 2021, 13, .	12.4	56
11	RGTAÂ® or ReGeneraTing Agents mimic heparan sulfate in regenerative medicine: from concept to curing patients. Glycoconjugate Journal, 2017, 34, 325-338.	2.7	55
12	Age-related Changes in Rat Myocardium Involve Altered Capacities of Glycosaminoglycans to Potentiate Growth Factor Functions and Heparan Sulfate-altered Sulfation. Journal of Biological Chemistry, 2012, 287, 11363-11373.	3.4	46
13	Glycosaminoglycans from Alzheimerâ€™s disease hippocampus have altered capacities to bind and regulate growth factors activities and to bind tau. PLoS ONE, 2019, 14, e0209573.	2.5	42
14	Heparan sulfate proteoglycans as key regulators of the mesenchymal niche of hematopoietic stem cells. Glycoconjugate Journal, 2017, 34, 377-391.	2.7	39
15	SLC10A7 mutations cause a skeletal dysplasia with amelogenesis imperfecta mediated by GAG biosynthesis defects. Nature Communications, 2018, 9, 3087.	12.8	39
16	Synthesis and biological activities of a library of glycosaminoglycans mimetic oligosaccharides. Biomaterials, 2011, 32, 769-776.	11.4	38
17	Glycosaminoglycans, Protein Aggregation and Neurodegeneration. Current Protein and Peptide Science, 2011, 12, 258-268.	1.4	36
18	Glycosaminoglycan mimeticsâ€“induced mobilization of hematopoietic progenitors and stem cells into mouse peripheral blood: Structure/function insights. Experimental Hematology, 2009, 37, 1072-1083.	0.4	35

#	Article	IF	Citations
19	Glycosaminoglycan mimetics inhibit SDF-1/CXCL12-mediated migration and invasion of human hepatoma cells. Glycobiology, 2009, 19, 1511-1524.	2.5	34
20	Glycosaminoglycans from aged human hippocampus have altered capacities to regulate trophic factors activities but not Aî²42 peptide toxicity. Neurobiology of Aging, 2012, 33, 1005.e11-1005.e22.	3.1	22
21	Altered heparan sulfate metabolism during development triggers dopamine-dependent autistic-behaviours in models of lysosomal storage disorders. Nature Communications, 2021, 12, 3495.	12.8	20
22	Glycosaminoglycan Mimetic Associated to Human Mesenchymal Stem Cell-Based Scaffolds Inhibit Ectopic Bone Formation, but Induce Angiogenesis In Vivo. Tissue Engineering - Part A, 2013, 19, 1641-1653.	3.1	19
23	Structureâ€“activity studies of heparan mimetic polyanions for anti-prion therapies. Biochemical and Biophysical Research Communications, 2007, 363, 95-100.	2.1	18
24	A heparan sulfate-based matrix therapy reduces brain damage and enhances functional recovery following stroke. Theranostics, 2018, 8, 5814-5827.	10.0	14
25	Molecular imprinting technology for specific recognition of heparan sulfate like disaccharides. Talanta, 2012, 99, 833-839.	5.5	12
26	New methods based on capillary electrophoresis for in vitro evaluation of protein tau phosphorylation by glycogen synthase kinase 3-Î². Analytical and Bioanalytical Chemistry, 2015, 407, 2821-2828.	3.7	11
27	Selfâ€evolving oxidative stress with identifiable preâ€and postmitochondrial phases in PC12 cells. Journal of Neuroscience Research, 2013, 91, 273-284.	2.9	3
28	Variation in Chst8 gene expression level affects PrPC to PrPSc conversion efficiency in prion-infected Mov cells. Biochemical and Biophysical Research Communications, 2011, 414, 587-591.	2.1	2
29	Heparan sulfates and the decrease of N-glycans promote early adipogenic differentiation rather than myogenesis of murine myogenic progenitor cells. Differentiation, 2017, 93, 15-26.	1.9	2
30	Protective Effects of a synthetic glycosaminoglycan mimetic (OTR4132) in a rat immunotoxic lesion model of septohippocampal cholinergic degeneration. Glycoconjugate Journal, 2022, 39, 107-130.	2.7	0